We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+3.34%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$17.4B
AUM Growth
+$71.8M
Cap. Flow
-$218M
Cap. Flow %
-1.26%
Top 10 Hldgs %
90.2%
Holding
115
New
7
Increased
18
Reduced
11
Closed
14

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$27.7M
2
ABCL icon
AbCellera Biologics
ABCL
+$26.2M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$23.1M
4
DNLI icon
Denali Therapeutics
DNLI
+$21.2M
5
GLUE icon
Monte Rosa Therapeutics
GLUE
+$12.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$63.1M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$55.9M
3
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$48.1M
4
IMGN
Immunogen Inc
IMGN
+$28.7M
5
ANAB icon
AnaptysBio
ANAB
+$12.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.2%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SERA icon
76
Sera Prognostics
SERA
$84.4M
$2.82M 0.02%
1,515,342
-262,093
-15% -$626K
PCVX icon
77
Vaxcyte
PCVX
$9.32B
$2.49M 0.01%
48,885
– –
XNCR icon
78
Xencor
XNCR
$2.07B
$2.48M 0.01%
123,127
– –
KALA icon
79
KALA BIO
KALA
$15.9M
$2.37M 0.01%
5,332
+3,008
+129% +$1.97M
ACHL
80
DELISTED
Achilles Therapeutics
ACHL
$2.33M 0.01%
2,557,149
– –
IPSC icon
81
Century Therapeutics
IPSC
$375M
$2.3M 0.01%
1,149,340
– –
AFMD
82
DELISTED
Affimed
AFMD
$2.13M 0.01%
444,864
-214,819
-33% -$1.18M
CATX icon
83
Perspective Therapeutics
CATX
$377M
$2.09M 0.01%
763,970
+532,041
+229% +$2.48M
TIL icon
84
Instil Bio
TIL
$51.4M
$2.01M 0.01%
235,220
-28,469
-11% -$287K
PMVP icon
85
PMV Pharmaceuticals
PMVP
$71.1M
$1.98M 0.01%
322,024
– –
ANAB icon
86
AnaptysBio
ANAB
$1.71B
$1.91M 0.01%
106,197
-669,727
-86% -$12.8M
PNT
87
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$1.67M 0.01%
249,968
-919,135
-79% -$7.64M
ITOS
88
DELISTED
iTeos Therapeutics
ITOS
$1.65M 0.01%
150,346
– –
CYPH
89
Cypherpunk Technologies Inc
CYPH
$153M
$1.62M 0.01%
1,172,175
– –
ALGS icon
90
Aligos Therapeutics
ALGS
$41.7M
$1.55M 0.01%
83,056
– –
MRSN
91
DELISTED
Mersana Therapeutics
MRSN
$1.38M 0.01%
43,445
– –
VOR icon
92
Vor Biopharma
VOR
$1.38B
$1.34M 0.01%
31,692
– –
NVTA
93
DELISTED
Invitae Corporation
NVTA
$1.07M 0.01%
1,764,546
-7,116,558
-80% -$7.4M
RNAM
94
DELISTED
Avidity Biosciences
RNAM
$1.06M 0.01%
166,347
-633,104
-79% -$5.45M
BCEL
95
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$922K 0.01%
3,532,760
– –
GTH
96
DELISTED
Genetron Holdings Limited ADS
GTH
$370K ﹤0.01%
151,769
– –
TARA icon
97
Protara Therapeutics
TARA
$228M
$333K ﹤0.01%
199,671
– –
FHTX icon
98
Foghorn Therapeutics
FHTX
$420M
$225K ﹤0.01%
45,027
– –
SRZNW
99
DELISTED
Surrozen Inc Warrant
SRZNW
$34.3K ﹤0.01%
833,333
– –
ALLO icon
100
Allogene Therapeutics
ALLO
$722M
– –
-1,576,901
Closed -$7.84M
1 2 3
4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2023 Portfolio in Review

As of Q3 2023, Julian Baker held 115 positions worth $17.4B, up 0.42% from $17.3B the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Julian Baker's Q3 2023 filing shows 7 new, 18 increased, 11 reduced and 14 closed positions. Its largest new stake was Morphic Holding, Inc. Common Stock: 215,800 shares worth $4.94M. The largest sale was argenx, an estimated $63.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q3 2023 buy was Morphic Holding, Inc. Common Stock: 215,800 shares worth $4.94M.
  • Julian Baker added most to Roivant Sciences in Q3 2023, an estimated $27.7M increase.
  • Julian Baker's biggest Q3 2023 reduction was argenx, cutting an estimated $63.1M.
  • Julian Baker fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $55.9M.
  • Julian Baker's ten largest holdings make up 90% of its $17.4B portfolio in Q3 2023.
  • Julian Baker opened 7 new positions and closed 14 in Q3 2023.
  • Julian Baker's portfolio value rose 0.42% quarter-over-quarter to $17.4B.

Based on Baker Bros. Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.